Positive results for Avexa
Monday, 16 March, 2009
Melbourne biotech Avexa has reported positive results from its ongoing Phase IIb trial of apricitabine (ATC) in patients with HIV.
Apricitabine is also in Phase III trials for HIV patients with resistance to common antiretrovirals. Interim results in this trial are expected shortly.
The Phase IIb trial is an open label trial for people who have failed previous HIV treatments such as 3TC. After almost two years on the trial, no resistance to ATC has been identified and no serious adverse events have been reported.
Over 85 per cent of patients have HIV loads below detectable levels and CD4 cells on average were over 500 microlitres, the company said.
Defective sperm doubles pre-eclampsia risk in IVF patients
A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...
Free meningococcal B vaccines coming to the NT
The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
